BofA on Axsome Therapeutics (AXSM): 'post IP resolution we expect Axsome shares to benefit from scarcity value of high growth'
Tweet Send to a Friend
BofA Securities analyst Jason Gerberry reiterated a Buy rating and $174.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
